DexCom Target of Unusually High Options Trading (DXCM)
DexCom (NASDAQ:DXCM) saw unusually large options trading on Tuesday. Traders purchased 168 put options on the stock, American Banking News reports. This represents an increase of 118% compared to the typical volume of 77 put options.
DXCM has been the subject of a number of recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of DexCom in a research note on Friday. They now have a $46.00 price target on the stock. Separately, analysts at Raymond James reiterated an “outperform” rating on shares of DexCom in a research note on Thursday, August 7th. They now have a $46.00 price target on the stock, up previously from $44.00. Finally, analysts at Canaccord Genuity raised their price target on shares of DexCom from $40.00 to $48.00 in a research note on Thursday, August 7th. They now have a “buy” rating on the stock. One analyst has rated the stock with a sell rating, five have issued a hold rating and seven have assigned a buy rating to the company’s stock. DexCom has a consensus rating of “Hold” and an average price target of $41.00.
DexCom (NASDAQ:DXCM) traded down 2.19% on Tuesday, hitting $42.89. The stock had a trading volume of 713,681 shares. DexCom has a 1-year low of $25.49 and a 1-year high of $49.83. The stock has a 50-day moving average of $38.80 and a 200-day moving average of $38.57. The company’s market cap is $3.237 billion.
DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.01. The company had revenue of $58.80 million for the quarter, compared to the consensus estimate of $52.45 million. During the same quarter in the previous year, the company posted ($0.14) earnings per share. The company’s quarterly revenue was up 64.2% on a year-over-year basis. Analysts expect that DexCom will post $-0.31 EPS for the current fiscal year.
DexCom, Inc (NASDAQ:DXCM) is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.